Market Insights
Metabolomics is a novel, emerging, and dynamic field that studies metabolites and distinctive chemical fingerprints produced during cellular processes. Thus, it identifies and quantifies metabolites further with the help of analytical technologies and the application of bioinformatics, which extract information and analyze the same. Metabolomics, though currently at a nascent stage, will be widely used in the biopharma and biotech industries as a tool for biomarker drug development and information
. Being non-invasive in nature and closely linked to the phenotype, it is an ideal tool used in agricultural industries, pharmaceutical industries, and preventive healthcare. A rise in the number of clinical trials, awareness about nutritional products, toxicological testing data, and the rapid growth of metabolomics data analysis software and solutions are expected to propel the growth of this market.
The report titled “Metabolomics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall metabolomics market along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of product and service, application, indication, and different geographies.
The product and service type segment studied for analyzing the overall global metabolomics market is majorly segmented into metabolomics instruments and metabolomics bioinformatics tools and services. Metabolomics instruments are sub-segmented into separation tools and detection tools. Separation tools include high-performance liquid chromatography, gas chromatography, ultra-performance liquid chromatography, and capillary electrophoresis.
Detection tools comprise mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis. Metabolomics’ bioinformatics tools and services category is sub-segmented into bioinformatics tools and databases and bioinformatics services.
The global metabolomics market is segmented by application type into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. Based on indications, this market is categorized into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others.
Geographically, the global metabolomics market is studied for the following regional markets:
- North America
- Europe
- Germany
- France
- UK.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global metabolomics market.
Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global metabolomics market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global metabolomics market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.
Based on the type of product and service, the global metabolomics market is segmented as follows:
- Metabolomics Instruments
- Separation Tools
- High-Performance Liquid Chromatography
- Gas Chromatography
- Ultra-Performance Liquid Chromatography
- Capillary Electrophoresis
- Detection Tools
- Mass Spectrometry
- Nuclear Magnetic Resonance Spectroscopy
- Surface-Based Mass Analysis
- Metabolomics, Bioinformatics, Tools, and Services
- Bioinformatics Tools and Databases
- Bioinformatics Services
Metabolomics instruments occupy the largest share of the global metabolomics market. Metabolomics bioinformatics tools and services are a fast-growing segment during the forecast period. With further technological developments, bioinformatics tools have enhanced the untargeted metabolomics workflow, enabling researchers to identify metabolites from LC/MS data and assign their biological roles with respect to chemical pathways.
In the separation tools segment, high-performance liquid chromatography dominates the market. While ultra-performance liquid chromatography offers high efficiency and high-resolution chromatographic separation with reduced analysis time, it is also expected to be a rapidly growing market in the future. In the detection tool segment, mass spectrometry occupies the maximum share, with nuclear magnetic resonance spectroscopy showing fast adaptability and bright future market growth.
Based on the type of application, the global metabolomics market is segmented as follows:
- Biomarker Discovery
- Drug Discovery
- Functional Genomics
- Personalized Medicine
- Toxicology Testing
- Nutrigenomics
- Others
Biomarker discovery occupies the largest share of the global metabolomics market. Metabolomics techniques aid in the discovery of potential biomarkers and the understanding of the pathogeneses of numerous human diseases.
With advancements in analytical technology, it is possible to quantify the biomarkers from small amounts of specimens using minimally invasive or non-invasive procedures to facilitate high-throughput analysis for real-time application in clinical settings.
The next big market for metabolomics will be drug discovery. Metabolomics helps in diagnosing the disease by understanding the biochemical pathway, thus further aiding in drug identification, design, and customization according to therapeutic needs. Personalized medicine is anticipated to be the fastest-growing segment during the forecast period, with biotech and pharma companies investing heavily in its research and development.
Based on the type of indication, the global metabolomics market is segmented as follows:
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Inborn Errors of Metabolism
- Others
Cancer dominates the global metabolomics market by indication segmentation. Cancer study through metabolomics helps in revealing new biomarkers for cancer, which would help in future diagnosis, prognosis, and therapy. Cardiovascular chronic disease is the greatest public health burden globally.
Thus, the use of metabolomic profiling would help identify new biomarkers and mechanisms of CVD risk. Because a current clinical diagnosis of neurological diseases such as Parkinson’s and Alzheimer’s is inadequate, emerging metabolomics techniques aid in the discovery of biomarkers and biochemical pathways for improving future diagnosis and prognosis therapy.
For the purpose of this study, the global metabolomics market is geographically categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
North America dominates the global metabolomics market, followed by Europe. The key drivers are the surge in research and development funding by government and private players for metabolomics studies, rising demand for personalized medicine and toxicology testing, easy accessibility of technologically advanced products and their high adoption rate, and the presence of various metabolomics manufacturers.
Growing demand for personalized medicine and the large presence of analytical equipment manufacturers in Europe contribute to the growth of the metabolomics market. Asia Pacific has a significant growth opportunity for the metabolomics market due to the presence of a number of pharmaceutical and biotechnology companies and its initiatives in research and development, improving healthcare infrastructure, and emerging economies such as China, Japan, India, and Singapore.
